European Journal of Clinical Pharmacology

, Volume 59, Issue 3, pp 243–251 | Cite as

Paracetamol and metabolite pharmacokinetics in infants

  • Caroline D. van der Marel
  • Brian J. Anderson
  • Richard A. van Lingen
  • Nicholas H. G. Holford
  • Marien A. L. Pluim
  • Frank G. A. Jansman
  • John N. van den Anker
  • Dick Tibboel
Pharmacokinetics and Disposition



Data concerning metabolism of paracetamol in infants are scant. Previous studies have examined urinary metabolite recovery rates after a single dose of paracetamol in either neonates (<6 weeks) or children (3–9 years). There are no studies investigating infants.


Infants (n=47) undergoing major craniofacial surgery were given paracetamol 19–45 mg/kg 6-, 8-, or 12-hourly as either elixir or suppository formulation for postoperative analgesia, after a loading dose of 33–59 mg/kg rectally during the operation. Serum was assayed for paracetamol concentration in 40 of these infants at 5, 8, 11, 14, 17 and 20 h postoperatively. Urine samples were collected every 3 h for 24 h in 15 of these infants. The clearances of paracetamol to glucuronide and sulphate metabolites as well as the urinary clearance of unmetabolised paracetamol were estimated using non-linear, mixed-effects models.


Mean (±SD) age and weight of the patients were 11.8±2.5 months and 9.1±1.9 kg. Clearances of paracetamol to paracetamol-glucuronide (%CV) and to paracetamol-sulphate were 6.6 (11.5) l/h and 7.5 (11.5) l/h respectively, standardised to a 70-kg person using allometric '1/4 power' models. Glucuronide formation clearance, but not sulphate formation, was related to age and increased with age from a predicted value in a neonate of 2.73 l/h/70 kg to a mature value of 6.6 l/h/70 kg with a maturation half-life of 8.09 months. Urine clearance of paracetamol-glucuronide, paracetamol-sulphate and unchanged paracetamol (%CV) were, respectively, 2.65, 3.03 and 0.55 (28) l/h/70 kg. The urine clearance of unchanged paracetamol and metabolites was related to urine volume flow rate. Clearance attributable to pathways other than these measured in urine was not identifiable. The glucuronide/sulphate formation clearance ratio was 0.69 at 12 months of age. Sulphate metabolism contributed 50% towards paracetamol clearance.


Glucuronide formation clearance increases with age in the infant age range but sulphate formation does not. Renal clearance of paracetamol and its metabolites increases with urine flow rate. This and other studies show that paracetamol metabolism to glucuronide appears to be similar in infants and children, but in adults is increased in comparison with children. Oxidative pathways were undetectable in this infant study and may explain, in part, the reduced incidence of hepatotoxicity in infants.


Paracetamol Metabolism Infants 


  1. 1.
    't Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Acker JN (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 108:1089–1093PubMedGoogle Scholar
  2. 2.
    Prescott LF (1996) Paracetamol (paracetamol). A critical bibliographic review. Taylor and Francis Publishers, LondonGoogle Scholar
  3. 3.
    Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT (2000) Contribution of CYP2E1 and CYP3A to paracetamol reactive metabolite formation. Clin Pharmacol Ther 67:275–282PubMedGoogle Scholar
  4. 4.
    Bergman K, Muller L, Teigen SW (1996) Series: current issues in mutagenesis and carcinogenesis, no. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Mutat Res 349:263–288CrossRefPubMedGoogle Scholar
  5. 5.
    Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 96:1336–1345PubMedGoogle Scholar
  6. 6.
    van der Marel CD, van Lingen RA, Pluim MA, et al (2001) Analgesic efficacy of rectal versus oral paracetamol in children after major craniofacial surgery. Clin Pharmacol Ther 70:82–90PubMedGoogle Scholar
  7. 7.
    McGrath PA, Brigham MC (1992) The assessment of pain in children and adolescents. In: Turk DC, Melzack R (eds) Handbook of pain assessment. The Guilford Press, New York, pp 295–314Google Scholar
  8. 8.
    Beal SL, Sheiner LB, Boeckmann A (1999) Nonmem user's guide. Division of Pharmacology, University of California, San FranciscoGoogle Scholar
  9. 9.
    Lowenthal DT, Oie S, Van Stone JC, Briggs WA, Levy G (1976) Pharmacokinetics of paracetamol elimination by anephric patients. J Pharmacol Exp Ther 196:570–578PubMedGoogle Scholar
  10. 10.
    Anderson BJ, Woollard GA, Holford NHG (2000) A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 50:125–134PubMedGoogle Scholar
  11. 11.
    Holford NHG (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329–332Google Scholar
  12. 12.
    Peters HP (1983) Physiological correlates of size. In: Beck E, Birks HJB, Conner EF (eds) The ecological implications of body size. Cambridge University Press, Cambridge, pp 48–53Google Scholar
  13. 13.
    Prothero JW (1980) Scaling of blood parameters in animals. Comp Biochem Physiol A67:649–657CrossRefGoogle Scholar
  14. 14.
    Gabrielsson J, Weiner D (1994) Interspecies scaling. In: Gabrielsson J, Weiner D (eds) Pharmacokinetic and pharmacodynamic data analysis. Swedish Pharmaceutical Press Ltd, Stockholm, pp 153–171Google Scholar
  15. 15.
    West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122–126PubMedGoogle Scholar
  16. 16.
    West GB, Brown JH, Enquist BJ (1999) The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677–1679PubMedGoogle Scholar
  17. 17.
    van Lingen RA, Deinum JT, Quak JM, et al (1999) Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed 80:F59–F63PubMedGoogle Scholar
  18. 18.
    Miller RP, Roberts RJ, Fischer LT (1976) Paracetamol elimination kinetics in neonates, children and adults. Clin Pharmacol Ther 19:284–294PubMedGoogle Scholar
  19. 19.
    Alam SN, Roberts RJ, Fischer LJ (1977) Age-related differences in salicylamide and paracetamol conjugation in man. J Pediatr 90:130–135PubMedGoogle Scholar
  20. 20.
    Levy G, Khanna NN, Soda DM, Tsuzuki O, Stern L (1975) Pharmacokinetics of paracetamol in the human neonate; formation of acetaminophinglycuronide and sulphate in relation to plasma bilirubin concentration and D-glucoric acid excretion. Pediatrics 55:818–825PubMedGoogle Scholar
  21. 21.
    Anderson BJ, McKee AD, Holford NH (1997) Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 33:313–327Google Scholar
  22. 22.
    de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36:439–452PubMedGoogle Scholar
  23. 23.
    Miners JO, Osborne NJ, Tonkin AL, Birkett DJ (1992) Perturbation of paracetamol urinary metabolic ratios by urine flow rate. Br J Clin Pharmacol 34:359–362PubMedGoogle Scholar
  24. 24.
    Barraclough MA (1972) Effect of vasopressin on the reabsorption of phenacetin and its metabolites from the tubular fluid in man. Clin Sci 43:709–713PubMedGoogle Scholar
  25. 25.
    West JR, Smith HW, Chasis H (1948) Glomerular filtration rate, effective renal blood flow, and maximal tubular excretory capacity in infancy. J Pediatr 32:10–18Google Scholar
  26. 26.
    Prescott LF, Wright N (1973) The effects of hepatic and renal damage on paracetamol metabolism and excretion following overdosage. A pharmacokinetic study. Br J Pharmacol 49:602–613.PubMedGoogle Scholar
  27. 27.
    Warner A (1986) Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity. Clin Chem 32:721–727PubMedGoogle Scholar
  28. 28.
    Greene JW, Craft L, Ghishan F (1983) Paracetamol poisoning in infancy. Am J Dis Child 137:386–387PubMedGoogle Scholar
  29. 29.
    al Obaidy SS, Li Wan Po A, McKiernan PJ, Glasgow JF, Millership J (1995) Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease. J Pharm Biomed Anal 13:1033–1039CrossRefPubMedGoogle Scholar
  30. 30.
    Roberts I, Robinson MJ, Mughal MZ, Ratcliffe JG, Prescott LF (1984) Paracetamol metabolites in the neonate following maternal overdose. Br J Pharmacol 18:201–206Google Scholar
  31. 31.
    Mitchell MC, Hanew T, Meredith CG, Schenker S (1983) Effects of oral contraceptive steroids on paracetamol metabolism and elimination. Clin Pharmacol Ther 34:48–53PubMedGoogle Scholar
  32. 32.
    Sonne J, Poulsen HE, Loft S, et al (1988) Therapeutic doses of codeine have no effect on paracetamol clearance or metabolism. Eur J Clin Pharmacol 35:109–111PubMedGoogle Scholar
  33. 33.
    Mitchell MC, Schenker S, Speeg KV, Jr (1984) Selective inhibition of paracetamol oxidation and toxicity by cimetidine and other histamine H2-receptor antagonists in vivo and in vitro in the rat and in man. J Clin Invest 73:383–391PubMedGoogle Scholar
  34. 34.
    Miners JO, Penhall R, Robson RA, Birkett DJ (1988) Comparison of paracetamol metabolism in young adult and elderly males. Eur J Clin Pharmacol 35:157–160PubMedGoogle Scholar
  35. 35.
    Wynne HA, Cope LH, Herd B, Rawlins MD, James OF, Woodhouse KW (1990) The association of age and frailty with paracetamol conjugation in man. Age Ageing 19:419–424PubMedGoogle Scholar
  36. 36.
    Hoffman DA, Wallace SM, Verbeeck RK (1990) Circadian rhythm of serum sulphate levels in man and paracetamol pharmacokinetics. Eur J Clin Pharmacol 39:143–148Google Scholar
  37. 37.
    Baraka OZ, Truman CA, Ford JM, Roberts CJ (1990) The effect of propranolol on paracetamol metabolism in man. Br J Clin Pharmacol 29:261–264PubMedGoogle Scholar
  38. 38.
    Rumble RH, Roberts MS, Denton MJ (1991) Effects of posture and sleep on the pharmacokinetics of paracetamol (paracetamol) and its metabolites. Clin Pharmacokinet 20:167–173PubMedGoogle Scholar
  39. 39.
    Miners JO, Robson RA, Birkett DJ (1986) Paracetamol metabolism in pregnancy. Br J Clin Pharmacol 22:359–362PubMedGoogle Scholar
  40. 40.
    Miners JO, Attwood J, Birkett DJ (1984) Determinants of paracetamol metabolism: effect of inducers and inhibitors of drug metabolism on paracetamol's metabolic pathways. Clin Pharmacol Ther 35:480–486PubMedGoogle Scholar
  41. 41.
    Ismail S, Na Bangchang K, Karbwang J, Back DJ, Edwards G (1995) Paracetamol disposition in Thai patients during and after treatment of falciparum malaria. Eur J Clin Pharmacol 48:65–69PubMedGoogle Scholar
  42. 42.
    Kamali F, Thomas SH, Ferner RE (1993) Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 35:58–61PubMedGoogle Scholar
  43. 43.
    Haderslev KV, Sonne J, Poulsen HE, Loft S (1998) Paracetamol metabolism in patients with ulcerative colitis. Br J Clin Pharmacol 46:513–516CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Caroline D. van der Marel
    • 1
  • Brian J. Anderson
    • 5
  • Richard A. van Lingen
    • 6
  • Nicholas H. G. Holford
    • 8
  • Marien A. L. Pluim
    • 3
  • Frank G. A. Jansman
    • 7
  • John N. van den Anker
    • 4
    • 9
    • 10
  • Dick Tibboel
    • 1
    • 2
  1. 1.Department of Paediatric SurgeryErasmus MC-SophiaThe Netherlands
  2. 2.Intensive Care Unit Pediatric SurgeryErasmus MC-SophiaRotterdamThe Netherlands
  3. 3.Department of PharmacyErasmus MC-SophiaThe Netherlands
  4. 4.Department of PaediatricsErasmus MC-SophiaThe Netherlands
  5. 5.Department of AnaesthesiaUniversity Hospital MaastrichtThe Netherlands
  6. 6.Department of PaediatricsIsala Clinics ZwolleThe Netherlands
  7. 7.Department of PharmacyIsala Clinics ZwolleThe Netherlands
  8. 8.Department of Pharmacology and Clinical PharmacologyUniversity of AucklandNew Zealand
  9. 9.Division of Pediatric Clinical PharmacologyChildren's National Medical CenterWashingtonUSA
  10. 10.Department of Pediatrics and PharmacologyGeorge Washington University Medical CenterWashingtonUSA

Personalised recommendations